Results 101 to 110 of about 2,075,366 (204)

RECOGNIZING, DIAGNOSING, AND TREATING TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): TARGETING CONTINUING MEDICAL EDUCATION (CME) TO THOSE WHO AREN’T TREATING ATTR-CM

Journal of the American College of Cardiology, 2021
Yvette M. Murley, Steve Bender, Marlene O. Heeg, Jonathan S. Simmons, Denise C. LaTemple, Grace Lin   +5 more
openaire   +1 more source

Living with Transthyretin amyloid cardiomyopathy from a patient perspective

BMC Cardiovascular Disorders
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition for which disease-modifying therapies are increasingly available. However, limited research has explored the patient experience with ATTR-CM and its impact on quality of
Quan M. Bui, Julia McCain, Larry A. Allen, Eric D. Adler, Cheryl Anderson, Cinnamon Bloss, Borsika A. Rabin, Marcus A. Urey   +7 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block [PDF]

OBJECTIVE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiac disorder caused by deposition of wild type or mutated transthyretin.
Bakalakos, Athanasios, Cannie, Douglas, Elliott, Perry M, Heenan, Imogen, Menezes, Leon, Patel, Kush, Protonotarios, Alexandros, Syrris, Petros   +7 more
core  

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence

The Egyptian Heart Journal
Background Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage.
Ikponmwosa Jude Ogieuhi, Oshomoh Mark-Anthony Ugiomoh, Kudzaishe Muzofa, Kristen Callender, Johnson David Ayodeji, Nnokam Prayer Nnekachi, Barkavi Thiyagarajan, Emmanuel Obokhai Uduigwome, Abhay Kapoor, Moses Chukwuebuka Odoeke, Reem Gamaleldin Hassan Mohamed, Courage Idahor   +11 more
doaj   +1 more source

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction [PDF]

Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure (HF). Methods This epidemiology study assessed the international prevalence of ATTR-CM among patients aged ≥60 years with a history of HF, left ...
Anderson, LJ, Angeli, FS, Cariou, E, Ebede, B, Garcia-Pavia, P, Palladini, G, Wang, R, Yun, S   +7 more
core   +1 more source

Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)

Cardiology and Therapy
Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related ...
Sepideh Attal, Jason Kemner, Jose Alvir, Sebastian Barth, Sofia Schuessler   +4 more
doaj   +1 more source

Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Many patients with ATTR-CM present with a mixed phenotype of both cardiac and neurologic symptoms, but real-world effectiveness studies of tafamidis in this ...
Jonas Wixner, Angela Dispenzieri, Leslie Amass, Martin Carlsson, Steve Riley, Evan Powers, Jeffery W. Kelly, the THAOS investigators   +7 more
doaj   +1 more source

Multimodal imaging in the assessment of disease phenotypes, progression, and prognosis of Cardiac Amyloidosis [PDF]

Background: Systemic amyloidoses are characterised by deposition of misfolded proteins within the extracellular space of multiple organs. Cardiac amyloid deposition results in a progressive decline in cardiac function, manifesting clinically as heart ...
Patel, Rishi
core  

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Cardiology and Therapy
Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to
Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M. Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H. Sheikh   +7 more
doaj   +1 more source

Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting. [PDF]

BMJ Open, 2023
Tsang C, Huda A, Norman M, Dickerson C, Leo V, Brownrigg J, Mamas M, Elliott P.   +7 more
europepmc   +1 more source